Genprex (GNPX) Featured in Audio Publication Discussing New Research on Breast Cancer Treatment
September 26 2019 - 8:30AM
via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces
the availability of a NetworkNewsAudio publication titled, “Gene
Therapies with Potential to Conquer Tough-to-Tackle Breast
Cancers.”
To hear the NetworkNewsWire Audio version, visit:
http://nnw.fm/wd8LJ
To read the full editorial, visit: http://nnw.fm/n7Txk
Treatment for breast cancer varies, based on both the patient’s
circumstances and type of cancer. The development of treatments to
suppress or even eliminate cancer has led to a high survival rate
in wealthy countries, with around 85% of patients in the United
States and United Kingdom surviving for at least five years from
diagnosis. But even in these countries, survival depends upon the
exact form of the cancer, how far it has progressed and whether a
treatment has been developed for that particular form. Cancer is a
difficult disease to defeat, and survival can depend upon the
ability of scientists to counter a specific genetic defect in a
specific set of cells.
Because cancers are so varied and challenging to tackle, every
individual win is worth celebrating. That’s why recent news
relating to triple-negative breast cancer (TNBC) has brought
excitement both for independent researchers and for Genprex
Inc. (NASDAQ:GNPX), a clinical-stage, gene-therapy company
whose tumor suppressor candidate 2 (TUSC2) was found to prevent
tumor growth in TNBC.
About Genprex Inc.
Genprex Inc. is a clinical-stage, gene-therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer-fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell-signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. Visit the company’s web site
at www.genprex.com or follow Genprex on Twitter
at twitter.com/genprex, Facebook
at facebook.com/genprexinc and LinkedIn
at linkedin.com/company/genprex.
About NetworkNewsAudio
NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution,
allows you to sit back and listen to market updates, CEO interviews
and a Company AudioPressRelease (APR). These audio clips provide
snapshots of position, opportunity and
momentum. NetworkNewsAudio (NNA) can assist your company
by cutting through the overload of information in today's market,
NNA brings its clients unparalleled visibility, recognition and
brand awareness. NetworkNewsWire (NNW) is where news,
content and information converge. NetworkNewsWire
(NNW) is a comprehensive provider of news aggregation and
syndication, enhanced press release services and a full array of
social communication solutions. As a multifaceted financial news
and distribution company with an extensive team of journalists and
writers, NNW has the unparalleled ability to reach a wide audience
of investors, consumers, journalists and the general public with an
ever-growing distribution network of more than 5,000 key
syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications:
NetworkWire (NW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkWire.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024